20.500.12556/DiRROS-18723 Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that the combination of bevacizumab and irinotecan is beneficial. Patients and methods. The medical documentation of 19 adult patients with recurrent malignant gliomas was retrospectively reviewed. All patients received bevacizumab (10 mg/kg) and irinotecan (340 mg/m2 or 125 mg/m2) every two weeks. Patient clinical characteristics, drug toxicities, response rate, progression free survival (PFS) and overall survival (OS) were evaluated. Results. Between August 2008 and November 2011, 19 patients with recurrent malignant gliomas (median age 44.7, male 73.7%, WHO performance status 0%2) were treated with bevacizumab/irinotecan regimen. Thirteen patients had glioblastoma, 5 anaplastic astrocytoma and 1 anaplastic oligoastrocytoma. With exception of one patient, all patients had initially a standard therapy with primary resection followed by postoperative chemoradiotherapy. Radiological response was confirmed after 3 months in 9 patients (1 complete response, 8 partial responses), seven patients had stable disease and three patients have progressed. The median PFS was 6.8 months (95% confidence interval [CI]: 5.3-8.3) with six-month PFS rate 52.6%. The median OS was 7.7 months (95% CI: 6.6-8.7), while six-month and twelve-month survival rates were 68.4% and 31.6%, respectively. There were 16 cases of hematopoietic toxicity grade (G) 1-2. Non-hematopoietic toxicity was present in 14 cases, all G1-2, except for one patient with proteinuria G3. No grade 4 toxicities, no thromboembolic event and no intracranial hemorrhage were observed. Conclusions. In recurrent malignant gliomas combination of bevacizumab and irinotecan might be an active regimen with acceptable toxicity. recurrent malignant glioma systemic therapy bevacizumab maligni gliom bevacizumab irinotecan sistemska terapija true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-04-17 13:15:47 2024-04-17 13:15:48 2024-04-18 03:46:10 0000-00-00 00:00:00 2015 0 0 str. 80-85, VI no. 1 Vol. 49 Mar. 2015 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2015-03-01 616.8-006 1318-2099 10.2478/raon-2014-0021 1813371 RAZ_Mesti_Tanja_2015.pdf RAZ_Mesti_Tanja_2015.pdf 1 9E8FC7EE5F8AE0DF84FC237948A95CEA 04e4ce877e5b062a6d23b50237b27e83043d02042969a555631606259c4078e9 3f53aea1-fc9b-11ee-ae20-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=25611 Onkološki inštitut Ljubljana 0 0 0